

NOVO NORDISK A S  
Form 6-K  
July 27, 2015  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 6-K

---

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

July 27, 2015

---

NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

Novo Allé  
DK- 2880, Bagsvaerd  
Denmark  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F       Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

**Novo Nordisk A/S – Share repurchase programme**

**Bagsværd, Denmark, 27 July 2015** – On 30 April 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to

Edgar Filing: NOVO NORDISK A S - Form 6-K

DKK 17.5 billion to be executed during a 12-month period beginning 30 January 2015.

Under the programme initiated 30 April 2015, Novo Nordisk will repurchase B shares for an amount up to DKK 9.3 billion in the period from 30 April 2015 to 27 October 2015.

Since the announcement as of 20 July 2015, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	<b>10,329,200</b>		<b>3,898,721,543</b>
20 July 2015	190,000	407.05	77,339,025
21 July 2015	212,000	403.29	85,498,434
22 July 2015	188,000	400.01	75,201,241
23 July 2015	215,000	398.17	85,606,701
24 July 2015	193,000	398.36	76,884,020
Accumulated under the programme	11,327,200		4,299,250,963

With the transactions stated above, Novo Nordisk owns a total of 31,116,891 B shares of DKK 0.20, corresponding to 1.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,600,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17.5 billion during a 12-month period beginning 30 January 2015. As of 24 July 2015, Novo Nordisk has



Lars Rebien Sørensen,  
Chief Executive Officer